UnknownNot Applicable

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

China30 participantsStarted 2018-10-25

Plain-language summary

The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged between 18 and 70 years old, either sex;
✓. Karnofsky performance status ≥ 70;
✓. Patients who were suffered drug-resistant,which has taken cabergoline ≥2.0mg/week no less than 3 months, referring to failure to normalize PRL levels and failure to decrease macroprolactinoma size by \>or=50%;
✓. The patient has signed the informed consent.

Exclusion criteria

✕. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated PRL ;
✕. Patients with parkinson disease and is taking dopaminergic agents;
✕. Patients with prolactinoma who received Gamma knife treatment;
✕. Patients who use any dopamine receptor agonists other than cabergoline;
✕. pregnant or lactating women, or women preparing pregnant;
✕. Patients with poor compliance, who cannot implement the program strictly.
✕. History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ.
✕. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, as HCQ may cause hemolytic anemia in patients with G6PD deficiency.

What they're measuring

Change from baseline on prolactin(PRL) level

Timeframe: Up to 6 months

Trial details

NCT IDNCT03400865

SponsorZhebao Wu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-30

Contact for this trial

Shaojian Lin, MD

0086-15801782758 shaojianlin88@126.com

View on ClinicalTrials.gov More Resistance, Disease trials